Scarica l'app Stockscreener
3.25
2.69%
-0.09
Pre-mercato:
3.24
-0.010
-0.31%
Rezolute Inc Borsa (RZLT) Ultime notizie
RZLT Stock Price, Quote & Chart | REZOLUTE INC (NASDAQ:RZLT) - ChartMill
Opaleye Management Inc. Increases Stake in Rezolute Inc. - GuruFocus
Balyasny holds 5,048,421 shares of Rezolute (NASDAQ: RZLT), ~5.28% stake - Stock Titan
RZLT Maintains by Maxim Group -- Price Target Raised to $10.00 - GuruFocus
FDA review puts Rezolute's genetic disorder drug path in question - MSN
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Wedbush Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $10 - Moomoo
High Growth Tech Stocks in US for May 2026 - simplywall.st
H.C. Wainwright reiterates Buy on Rezolute stock, $5 target - Investing.com UK
H.C. Wainwright reiterates Buy on Rezolute stock, $5 target By Investing.com - Investing.com Nigeria
TradingKey - TradingKey
Rezolute (RZLT) Q3 FY2026 Earnings: EPS Not Disclosed, Revenue N - GuruFocus
RZLT Reports Significant Decrease in Cash Reserves - GuruFocus
Rezolute, Inc. 3Q 2026: Net loss $16.2M, EPS $(0.16) — 10-Q Summary - TradingView
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update - The Manila Times
Rezolute (NASDAQ: RZLT) details sunRIZE miss and tumor HI Phase 3 - Stock Titan
Rezolute 3Q Loss/Shr 16c >RZLT - Moomoo
Rezolute (NASDAQ: RZLT) Q3 2026 loss narrows with HI efficacy data - Stock Titan
MSN Money - MSN
Rezolute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
Opaleye-affiliated holders report 6.3M shares in Rezolute (RZLT) - Stock Titan
Number of shareholders of Rezolute, Inc. – NASDAQ:RZLT - TradingView
Rezolute Inc. to Present Clinical Development Programs at Investor Conferences - geneonline.com
Rezolute to Participate in Upcoming Investor Conferences - The Manila Times
About Us | Oil & Gas JournalRezolute to Participate in Upcoming Investor Conferences - FinancialContent
Rezolute Announces Positive Phase 3 sunRIZE Results for Ersodetug in Congenital Hyperinsulinism, Shows Significant Glycemic Improvements and FDA Progress 1234 - Minichart
Rezolute Shares Expanded Phase 3 sunRIZE Data With FDA - TipRanks
Phase 3 sunRIZE miss but strong CGM gains for Rezolute (NASDAQ: RZLT) - Stock Titan
Rezolute Buy Rating Reiterated as CGM Data Offset Phase 3 Miss; $5 Price Target Maintained - TipRanks
H.C. Wainwright reiterates Rezolute stock rating on CGM data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Rezolute stock rating on CGM data - Investing.com
Rezolute presents expanded Phase 3 data for hyperinsulinism drug By Investing.com - Investing.com Australia
Rezolute (RZLT) Presents Positive Findings from Phase 3 sunRIZE Study - GuruFocus
Rezolute presents expanded Phase 3 data for hyperinsulinism drug - Investing.com
Rezolute, Inc. Reports Positive Continuous Glucose Monitoring Outcomes for Ersodetug in Phase 3 sunRIZE Study of Congenital Hyperinsulinism - Quiver Quantitative
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in ... - Caledonian Record
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting - The Killeen Daily Herald
Rezolute Stock: FDA Fast Track Fuels 2025 Breakout - MSN
Rezolute shares in focus after RA Capital discloses 9.9% stake - MSN
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):